Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07282093 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 23, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 31, 2025 to Nov 11, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 31, 2025 to Nov 11, 2025
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a non-randomized, open-label, parallel, single-dose study to evaluate the pharmacokinetic profile of olverembatinib in participants with normal or impaired liver function.
Trial Details
NCT Number NCT07282093
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Guangzhou Healthquest Pharma Co., Ltd
Conditions Pharmacokinetic, Olverembatinib
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov